Preferential uptake of chitosan-coated PLGA nanoparticles by primary human antigen presenting cells

A Multi-epitope Peptide rOmp22 Encapsulated in Chitosan-PLGA Nanoparticles as Vaccine Candidate Against Acinetobacter baumannii Infection

“…The sustained slow release of the peptide was an attractive property for a vaccine candidate as this might reduce the number of immunizations as well as enhancing the presentation of the peptide to APCs. Cell toxicity studies showed that CS-PLGA NPs was not toxic to cells at concentration as high as 800 µg/ml, thus indicating the safety of this delivery system as reported by several researchers [27,28].…”

“…Poly (lactic-co-glycolic) acid (PLGA) is a synthetic copolymer that has been approved by United States Food and Drug Administration (FDA) and European Medicine Agency (EMA) for various medical and pharmaceutical applications in humans [25]. PLGA NPs have been shown to be e cient for antigen delivery because of their effectiveness in enhancing immune responses, controlled release, high encapsulation e ciency and tissue bio-distribution, along with being biodegradable, non-toxic and small in size [26][27][28]. While PLGA NPs display many advantages in antigen delivery, in comparison with cationic bio/polymers, they can suffer poor encapsulation e ciency and instable when loading negatively charged molecules, such as protein or peptide antigen.…”

“…Chitosan (CS) is a non-toxic and non-immunogenic naturally occurring linear amino poly-saccharide (poly 1,4-dayglucoamine), with an ability to enhance the penetration of large molecules across mucosal surfaces [29]. Such anionic PLGA NPs can be subjected to chitosan-surface coating, thus resulting in cationic chitosancoated PLGA (CS-PLGA) NPs, which hold promise as innovative formulations for targeted delivery [27]. Previous studies have demonstrated that CS-PLGA NPs are particularly effective for antigen delivery to APC, such as inducing antigen presentation to lymphocytes or modulating APC function [27].…”

“…Such anionic PLGA NPs can be subjected to chitosan-surface coating, thus resulting in cationic chitosancoated PLGA (CS-PLGA) NPs, which hold promise as innovative formulations for targeted delivery [27]. Previous studies have demonstrated that CS-PLGA NPs are particularly effective for antigen delivery to APC, such as inducing antigen presentation to lymphocytes or modulating APC function [27].…”

The Design of Poly(lactide-co-glycolide) Nanocarriers for Medical Applications

“…Poly lactide-co-glycolide has been adapted to treat conditions in many fields of biomedicine, as shown by Figure 12 (Mir et al, 2017). A hyaluronic acid functionalized PLGA based nanocarrier for methatrexate has been developed for targeted treatment of rheumatoid arthritis (Trujillo-Nolasco et al, 2019), a PLGA nanoparticle with protease inhibitor has shown to overcome gastro-intestinal limitations of oral insulin delivery in rats (Faheem et al, 2019), a PLGA-chitosan based nanocarrier has been synthesized and shown to be selective for human antigen presenting cells (Durán et al, 2019), a potential DNA vaccine delivery system has been designed using a PLGA based nanocarrier (Besumbes et al, 2019), and a Vitamin D encapsulated PLGA based delivery system has recently shown activity against various markers for Alzheimer's disease in mice (Jeon et al, 2019). Gonzalez-Pizarro et al (2018) have prepared an optimized fluoromethalone-PLGA nanoparticle that demonstrated increased efficacy in treating ocular inflammation compared to the commercial formula.…”